预防公卫威廉亚洲博彩公司

订阅

MedSci主页 / 所有栏目 / 预防公卫威廉亚洲博彩公司

中国老年人疫苗接种的现状、挑战和建议

2022-08-22 中国疫苗和免疫

疫苗接种老年人疫苗接种

老年人群传染病的疾病负担高而且治疗和康复难度大。常见疫苗可预防传染病如流感、肺炎球菌疾病、带状疱疹等对老年人健康造成重大威胁，而接种疫苗是预防这些疾病最经济有效的手段。目前中国老年人预防接种服务可及性

中文标题：

中国老年人疫苗接种的现状、挑战和建议

发布机构：

发布日期：

2022-08-22

简要介绍：

老年人群传染病的疾病负担高而且治疗和康复难度大。常见疫苗可预防传染病如流感、肺炎球菌疾病、带状疱疹等对老年人健康造成重大威胁，而接种疫苗是预防这些疾病最经济有效的手段。目前中国老年人预防接种服务可及性差，疫苗接种率较低。本文根据现有国内外文献，对中国老年人疫苗接种的现状和挑战进行了综述，对老年人疫苗接种提出了相关建议。 

相关资料下载：
[AttachmentFileName(sort=1, fileName=中国老年人疫苗接种的现状、挑战和建议_王雯.pdf)] GetToolGuiderByIdResponse(projectId=1, id=7e5d91c0026203af, title=中国老年人疫苗接种的现状、挑战和建议, enTitle=, guiderFrom=中国疫苗和免疫, authorId=0, author=, summary=老年人群传染病的疾病负担高而且治疗和康复难度大。常见疫苗可预防传染病如流感、肺炎球菌疾病、带状疱疹等对老年人健康造成重大威胁，而接种疫苗是预防这些疾病最经济有效的手段。目前中国老年人预防接种服务可及性, cover=https://img.medsci.cn/Random/multiple-sclerosis-s14-doctor-speaking-with-patient.jpg, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Mon Aug 22 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #666666;">老年人群传染病的疾病负担高而且治疗和康复难度大。常见疫苗可预防传染病如流感、肺炎球菌疾病、带状疱疹等对老年人健康造成重大威胁，而接种疫苗是预防这些疾病最经济有效的手段。目前中国老年人预防接种服务可及性差，疫苗接种率较低。本文根据现有国内外文献，对中国老年人疫苗接种的现状和挑战进行了综述，对老年人疫苗接种提出了相关建议。&nbsp;</span></p>, tagList=[TagDto(tagId=7819, tagName=疫苗接种), TagDto(tagId=459913, tagName=老年人疫苗接种)], categoryList=[CategoryDto(categoryId=35, categoryName=预防公卫, tenant=100), CategoryDto(categoryId=85, categoryName=威廉亚洲博彩公司 &解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=107875, articleKeyword=中老年人疫苗, articleKeywordNum=6, guiderKeywordId=107875, guiderKeyword=中老年人疫苗, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8666, appHits=121, showAppHits=0, pcHits=897, showPcHits=8545, likes=0, shares=3, comments=6, approvalStatus=1, publishedTime=Fri Aug 26 09:27:00 CST 2022, publishedTimeString=2022-08-22, pcVisible=1, appVisible=1, editorId=0, editor=lixiang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=5, createdBy=null, createdName=lixiang, createdTime=Wed Aug 24 11:10:09 CST 2022, updatedBy=6459136, updatedName=艺玮, updatedTime=Sat Jan 06 09:07:47 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=中国老年人疫苗接种的现状、挑战和建议_王雯.pdf)])
中国老年人疫苗接种的现状、挑战和建议_王雯.pdf
下载请点击：
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2126507, encodeId=717e212650e23, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa83166610, createdName=12b7ea7bm59暂无昵称, createdTime=Mon Apr 17 14:34:55 CST 2023, time=2023-04-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2126506, encodeId=a67821265067c, content=学习 学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa83166610, createdName=12b7ea7bm59暂无昵称, createdTime=Mon Apr 17 14:32:30 CST 2023, time=2023-04-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2121676, encodeId=ab4821216e626, content=学习学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20228578455, createdName=ms8000000684966679, createdTime=Fri Mar 24 22:29:39 CST 2023, time=2023-03-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2120440, encodeId=936a2120440f7, content=学习一下！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20228578455, createdName=ms8000000684966679, createdTime=Sun Mar 19 16:41:44 CST 2023, time=2023-03-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2120441, encodeId=ec76212044149, content=针对老人治疗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20228578455, createdName=ms8000000684966679, createdTime=Sun Mar 19 16:42:07 CST 2023, time=2023-03-19, status=1, ipAttribution=上海)]
    2023-04-17 12b7ea7bm59暂无昵称 来自江苏省

    学习一下

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2126507, encodeId=717e212650e23, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa83166610, createdName=12b7ea7bm59暂无昵称, createdTime=Mon Apr 17 14:34:55 CST 2023, time=2023-04-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2126506, encodeId=a67821265067c, content=学习 学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa83166610, createdName=12b7ea7bm59暂无昵称, createdTime=Mon Apr 17 14:32:30 CST 2023, time=2023-04-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2121676, encodeId=ab4821216e626, content=学习学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20228578455, createdName=ms8000000684966679, createdTime=Fri Mar 24 22:29:39 CST 2023, time=2023-03-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2120440, encodeId=936a2120440f7, content=学习一下！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20228578455, createdName=ms8000000684966679, createdTime=Sun Mar 19 16:41:44 CST 2023, time=2023-03-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2120441, encodeId=ec76212044149, content=针对老人治疗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20228578455, createdName=ms8000000684966679, createdTime=Sun Mar 19 16:42:07 CST 2023, time=2023-03-19, status=1, ipAttribution=上海)]
    2023-04-17 12b7ea7bm59暂无昵称 来自江苏省

    学习 学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2126507, encodeId=717e212650e23, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa83166610, createdName=12b7ea7bm59暂无昵称, createdTime=Mon Apr 17 14:34:55 CST 2023, time=2023-04-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2126506, encodeId=a67821265067c, content=学习 学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa83166610, createdName=12b7ea7bm59暂无昵称, createdTime=Mon Apr 17 14:32:30 CST 2023, time=2023-04-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2121676, encodeId=ab4821216e626, content=学习学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20228578455, createdName=ms8000000684966679, createdTime=Fri Mar 24 22:29:39 CST 2023, time=2023-03-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2120440, encodeId=936a2120440f7, content=学习一下！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20228578455, createdName=ms8000000684966679, createdTime=Sun Mar 19 16:41:44 CST 2023, time=2023-03-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2120441, encodeId=ec76212044149, content=针对老人治疗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20228578455, createdName=ms8000000684966679, createdTime=Sun Mar 19 16:42:07 CST 2023, time=2023-03-19, status=1, ipAttribution=上海)]
    2023-03-24 ms8000000684966679 来自上海

    学习学习！

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2126507, encodeId=717e212650e23, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa83166610, createdName=12b7ea7bm59暂无昵称, createdTime=Mon Apr 17 14:34:55 CST 2023, time=2023-04-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2126506, encodeId=a67821265067c, content=学习 学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa83166610, createdName=12b7ea7bm59暂无昵称, createdTime=Mon Apr 17 14:32:30 CST 2023, time=2023-04-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2121676, encodeId=ab4821216e626, content=学习学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20228578455, createdName=ms8000000684966679, createdTime=Fri Mar 24 22:29:39 CST 2023, time=2023-03-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2120440, encodeId=936a2120440f7, content=学习一下！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20228578455, createdName=ms8000000684966679, createdTime=Sun Mar 19 16:41:44 CST 2023, time=2023-03-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2120441, encodeId=ec76212044149, content=针对老人治疗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20228578455, createdName=ms8000000684966679, createdTime=Sun Mar 19 16:42:07 CST 2023, time=2023-03-19, status=1, ipAttribution=上海)]
    2023-03-19 ms8000000684966679 来自上海

    学习一下！

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2126507, encodeId=717e212650e23, content=学习一下, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa83166610, createdName=12b7ea7bm59暂无昵称, createdTime=Mon Apr 17 14:34:55 CST 2023, time=2023-04-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2126506, encodeId=a67821265067c, content=学习 学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faa83166610, createdName=12b7ea7bm59暂无昵称, createdTime=Mon Apr 17 14:32:30 CST 2023, time=2023-04-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2121676, encodeId=ab4821216e626, content=学习学习！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20228578455, createdName=ms8000000684966679, createdTime=Fri Mar 24 22:29:39 CST 2023, time=2023-03-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2120440, encodeId=936a2120440f7, content=学习一下！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20228578455, createdName=ms8000000684966679, createdTime=Sun Mar 19 16:41:44 CST 2023, time=2023-03-19, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2120441, encodeId=ec76212044149, content=针对老人治疗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20228578455, createdName=ms8000000684966679, createdTime=Sun Mar 19 16:42:07 CST 2023, time=2023-03-19, status=1, ipAttribution=上海)]
    2023-03-19 ms8000000684966679 来自上海

    针对老人治疗

    0

相关威廉亚洲博彩公司

2022 WHO 实现高接种率的工具和实用威廉亚洲博彩公司 ：疫苗接种的行为和社会驱动因素

世界卫生组织(WHO,The World Health Organization) · 2022-04-13

2022 NICE 威廉亚洲博彩公司 ：普通人群的疫苗接种情况 [NG218]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2022-05-17

中国疫苗接种用注射器(注射针)选用专家共识

中华预防医学会(CPMA,Chinese Preventive Medicine Association) · 2022-06-22

2021 EULAR/PRES建议：自身免疫性炎症性风湿病儿童的疫苗接种（更新版）

欧洲抗风湿病联盟(EULAR,The European League Against Rheumatism) · 2022-06-20

《2021年美国肝病学会专家共识声明： 肝病患者接种疫苗预防COVID-19感染》摘译

首都医科大学附属北京友谊医院肝病中心 · 2021-05-15

乳腺癌患者新冠疫苗接种中国专家共识

解放军总医院第五医学中心感染病医学部 · 2021-12-30

拓展阅读

GSK携手北京协和医学院群医学及公共卫生学院：以带状疱疹疾病医防协同为试点,，关注中老年人疫苗可预防疾病

11月6日，葛兰素史克 (GSK) 与中国医学科学院北京协和医学院群医学及公共卫生学院于第三届进博会上签订了公益项目合作备忘录，北京协和医学院群公学院教授、执行院长杨维中，GSK副总裁、中国处方药和疫